Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA foreign data for current fiscal year find that 68% of actionable inspections involve bulk drugs.

Executive Summary

FDA FOREIGN INSPECTIONS: 68% REQUIRING FURTHER ACTION ARE FOR BULK DRUGS during the current fiscal year, according to data compiled by FDA's international programs staff. About 70% of the inspections performed abroad during this time frame were on bulk facilities and 30% on finished dosage form plants. The inspections, when classified by degree of seriousness of the findings, show a proportional breakdown: 68% of the total number of inspections given FDA's "official action indicated" (OAI) designation -- meaning that follow-up enforcement action is warranted -- were for bulk drugs compared to 32% for finished drugs. Bulk drug inspections comprised 66% of those classified as "voluntary action indicated" (VAI) compared to 34% for dosage forms.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel